Welkin Health and Risalto Health Partner on New Program to Improve Health Outcomes for Individuals with Musculoskeletal Conditions

New concierge program helps care teams provide alternative pathways for patients with back, knee, and hip pain without the use of opioids.

Welkin Health, a San Francisco-based digital health company, has partnered with Risalto Health, a digital health services company transforming the delivery of musculoskeletal (MSK) care, to offer a new care concierge program aimed at streamlining the MSK patient journey and improving the outcomes of patients living with chronic back, knee, and hip pain.

“Millions of Americans are affected by an MSK condition. The physical and financial burden is heavy—and the $213 billion cost in annual treatment, care, and lost wages doesn’t begin to capture the suffering of living with chronic pain,” says Dan Pizzarello, MD, founder and CEO, Risalto Health. “Navigating quality care can be challenging, and as a result, MSK conditions often go untreated or people receive inadequate care. We are using data science and cutting-edge care management to create a patient journey that works. Working with Welkin allows us to focus on data and clinical programs while ensuring that patients receive individualized, continuous support, helping them to find relief and stay well.”

Risalto’s platform uses a proprietary algorithm to expertly connect patients, employers, and providers with high-quality care by delivering personalized, alternative solutions for patients with MSK conditions. Using Welkin’s configurable case management tool, their team member workflows will be customized and streamlined to best engage, treat, and follow up with patients suffering from lower back, knee or hip pain. Data captured between patients and care teams from Welkin’s six communication channels—such as phone, text, and email—will provide greater insights into patient behaviors, informing future patient care. Welkin’s workflow triggers enable users to quickly address patient needs, guaranteeing strengthened relationships and improved long-term outcomes.

Risalto and Welkin have enrolled their first customer in the concierge program—a Fortune 50 company with nearly 160,000 employees.

“As prescription painkillers continue to fuel an addiction epidemic, patients and providers are seeking alternative pathways to better manage pain resulting from MSK conditions,” says Chase Hensel, CEO and co-founder, Welkin Health. “Widening access to these effective therapies for patients, employers, and providers is what Risalto does so well. This new program will provide the level of high-touch patient service that MSK conditions demand, improving patient outcomes and reducing the costs accrued by mismanaged care.”